Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)

Author:

Lodise Thomas P.1ORCID,Van Wart Scott2,Sund Zoe M.3,Bressler Adam M.4,Khan Akram5,Makley Amy T.6,Hamad Yasir7ORCID,Salata Robert A.8,Silveira Fernanda P.9,Sims Matthew D.10,Kabchi Badih A.11,Saad Mohamed A.12,Brown Carrie13,Oler Randolph E.13,Fowler Vance14,Wunderink Richard G.15

Affiliation:

1. Albany College of Pharmacy and Health Sciences, Albany, New York, USA

2. Enhanced Pharmacodynamics, LLC, Buffalo, New York, USA

3. Duke University, Durham, North Carolina, USA

4. Infectious Disease Specialists of Atlanta, Decatur, Georgia, USA

5. Oregon Health and Science University, Portland, Oregon, USA

6. Department of Surgery, University of Cincinnati, Cincinnati, Ohio, USA

7. Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

8. Division of Infectious Diseases and HIV Medicine, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA

9. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

10. Beaumont Hospital, Royal Oak, Michigan, USA

11. Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA

12. University of Louisville, Louisville, Kentucky, USA

13. Emmes, Rockville, Maryland, USA

14. Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA

15. Northwestern University, Chicago, Illinois, USA

Abstract

Intravenous (i.v.) minocycline is increasingly used to treat infections caused by multidrug-resistant (MDR) Acinetobacter baumannii . Despite its being approved nearly 50 years ago, published information on its pharmacokinetic (PK) profile is limited. This multicenter study examined the PK and probability of pharmacokinetic-pharmacodynamic (PK-PD) target attainment profile of i.v. minocycline in critically ill patients, with suspected or documented infection with Gram-negative bacteria.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

HHS | NIH | OSC | Common Fund

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3